← Human Trials & Peer-Reviewed Studies
Adjuvant growth hormone therapy in poor responders to in-vitro fertilization: a prospective randomized placebo-controlled double-blind study.
Plain-language guide to PMID 7745068 (1995): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and HMG (Human Menopausal Gonadotropin).
Key Facts
- PMID
- 7745068
- Journal
- Human reproduction (Oxford, England)
- Year
- 1995
- Study type
- Randomized Controlled Trial
- Authors
- Dor J et al. (6 authors)
- DOI
- 10.1093/humrep/10.1.40
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and HMG (Human Menopausal Gonadotropin).
The objective of the study was to assess the effect of growth hormone (GH) supplementation to a combined gonadotrophin-releasing hormone agonist/human menopausal gonadotrophin (GnRHa/HMG) treatment protocol on ovarian response in 'poor responders' undergoing in-vitro fertilization (IVF).
Why It Was Studied
GH or a placebo were administered in a prospective randomized double-blind manner.
Who Took Part
By PubMed's age tags, the people studied were adults and middle-aged adults, women only.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
What Was Measured
PubMed files the paper under topics including Estradiol, Fertilization in Vitro, Follicular Fluid, Gonadotropin-Releasing Hormone, Growth Hormone, Hormones and Insulin-Like Growth Factor I.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and HMG (Human Menopausal Gonadotropin).
The publication is from 1995 (Human reproduction (Oxford, England)), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the HMG (Human Menopausal Gonadotropin) compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
HMG (Human Menopausal Gonadotropin): Menotropins: a glycoprotein preparation that supplies follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- HMG (Human Menopausal Gonadotropin) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.